Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $54.21, signifying a -4.71% move from its prior day's close.
Crispr Therapeutics: Patience And Opportunity Through Volatility
Crispr Therapeutics remains highly volatile, disconnected from near-term fundamentals, yet I see long-term value far above current levels. CRSP's business progress is slow, with pipeline milestones and cash runway—not quarterly EPS—being the most relevant metrics for investors. Key risks include the commercial ramp of Casgevy, pipeline execution, and surviving cash burn until anticipated profitability in 2028.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) closed at $53.84 in the latest trading session, marking a -4.54% move from the prior day.
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a +2.58% change from its previous close.
Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key
Crispr Therapeutics AG commands a $5bn valuation, anchored by Casgevy's commercial approval and robust clinical data in SCD and TDT. Casgevy's slow commercial ramp is expected to accelerate in 2026, with revenue and patient growth as key valuation drivers. CRSP's pipeline—spanning in-vivo, CAR-T, and diabetes assets—offers major upside, but Casgevy remains the only revenue source.
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.19, moving 1.45% from the previous trading session.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $56.46, marking a -2.5% move from the previous day.
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies
CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.
